For Research Purposes Only. This article is intended for laboratory and research audiences and does not constitute guidance for human or animal use.

What Is a Growth Hormone Secretagogue?

“Growth hormone secretagogue” (GHS) is an umbrella term for any compound that stimulates the body’s own secretion of growth hormone — working through existing regulatory pathways rather than supplying growth hormone directly. That single definition covers two mechanistically distinct peptide classes that are frequently discussed together in the literature but act on entirely different receptors.

Treating “GH secretagogue” as one category obscures more than it explains. Understanding which class a given compound belongs to — and why that matters mechanistically — is the more useful starting point for any research protocol involving GH-pathway peptides.

The Two Mechanistic Classes

Class 1: GHRH Analogs

These peptides interact directly with GHRH receptors in the anterior pituitary, stimulating the same synthesis and secretion pathway that endogenous growth hormone-releasing hormone (GHRH) uses. Studied compounds in this class include tesamorelin, CJC-1295, and sermorelin.

Because GHRH analogs work through the natural GHRH pathway, their effect remains subject to somatostatin’s inhibitory tone — they raise the baseline drive for GH production but stay within the body’s existing feedback system rather than overriding it. Tesamorelin is the most clinically established compound in this class, having completed Phase III trials and received FDA approval for a specific indication (see our dedicated Tesamorelin research overview for details).

Class 2: GHRP / Ghrelin Receptor Agonists

This class acts on a completely different receptor — GHSR-1a, the ghrelin receptor — rather than the GHRH receptor. Studied compounds include ipamorelin, hexarelin, GHRP-2, and GHRP-6. Mechanistically, these peptides amplify GH pulse amplitude and reduce somatostatin’s inhibitory tone, working synergistically with (rather than instead of) GHRH signaling — research has found their GH-releasing activity is synergistic with GHRH and is not blunted by opioid receptor antagonists, unlike some influences that nearly abolish GHRH’s own effect.

Within this class, selectivity varies significantly. Ipamorelin is frequently noted in the research literature for a more selective receptor interaction profile than earlier GHRPs, with limited observed interaction with prolactin and cortisol secretion pathways — a meaningful mechanistic distinction from earlier-generation compounds like GHRP-6, which show greater off-target cortisol and prolactin effects in studied models.

Why These Classes Are Often Studied Together

Because GHRH analogs and GHRP/ghrelin-receptor agonists act on distinct receptors, research has examined their combination specifically for interactive effects on GH pulse amplitude and frequency — the two mechanisms are complementary rather than redundant. Published clinical research on CJC-1295 specifically (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006) demonstrated prolonged stimulation of both GH and IGF-1 secretion in healthy adults, establishing pharmacokinetic groundwork that later combination research has built on.

What the Research Literature Covers

Receptor characterization and structural biology. A substantial body of foundational research has focused on characterizing the GHRH receptor itself — a Class B1 GPCR — including its two-step activation model and, more recently, its relevance as a potential drug target in oncology research given its overexpression in several cancer types.

Comparative pituitary research. Cross-species pituitary culture studies have examined how GHRH, ghrelin, and related peptides differentially regulate GH secretion across reptiles, birds, and mammals — research relevant to understanding how conserved (or divergent) these regulatory mechanisms are across vertebrate biology.

Selectivity and side-effect profiling. A recurring research theme across the GHRP/ghrelin-agonist class involves comparing selectivity profiles — specifically, which compounds stimulate GH release with minimal off-target effects on cortisol, prolactin, and appetite-related (orexigenic) pathways, since ghrelin receptor activation is also tied to feeding behavior in preclinical models.

Clinical-grade evidence (tesamorelin specifically). As covered in more depth in our dedicated Tesamorelin article, this is the one compound in the GHS space with Phase III trial data and FDA approval — a different evidence tier than the rest of the class, which remains largely preclinical or early-phase.

Purity and Research-Grade Considerations

Because GH secretagogue research often involves comparing or combining compounds from both mechanistic classes, batch-to-batch consistency is particularly important for interpreting combination studies. HPLC-verified purity and a batch-specific certificate of analysis (COA) remain the baseline standard for any compound in this class, whether studied individually or in combination protocols.

Shop our HPLC-verified Tesamorelin research peptide, the only clinically-established compound in this class, batch-tested for purity.

Summary

Growth hormone secretagogues split into two mechanistically distinct classes: GHRH analogs (including tesamorelin, CJC-1295, and sermorelin), which work through the pituitary’s natural GHRH receptor pathway, and GHRP/ghrelin receptor agonists (including ipamorelin and hexarelin), which act on a separate receptor to amplify GH pulse characteristics. Selectivity varies meaningfully within the second class, and only tesamorelin currently carries clinical-trial-grade evidence and regulatory approval — the rest of the category remains an active but earlier-stage area of research.

---

This article summarizes publicly available research literature for informational and research-planning purposes. It is not intended to diagnose, treat, cure, or prevent any disease, and does not constitute a recommendation for human or animal use. All products are sold for research use only.

Sources referenced: Casanueva & Dieguez, “Growth hormone secretagogues: physiological role and clinical utility,” Trends in Endocrinology & Metabolism (1999); Teichman et al., “Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295,” Journal of Clinical Endocrinology & Metabolism (2006); published research on GHRH receptor structural biology (PMC).